SCHEMBL23146830

SCHEMBL23146830

Cc1[nH]cc(C(=O)O)c(=O)c1-c1ccc(F)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.49
▸ CSNK2A1 P68400 3/20 0.43
▸ CSNK2A2 P19784 2/20 0.43
▸ CSNK2B P67870 2/20 0.43
▸ HPGD P15428 2/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ DHODH Q02127 2/20 0.41
▸ NOTUM Q6P988 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ BCL2L1 Q07817 1/20 0.40
▸ BAD Q92934 1/20 0.40
▸ PRKAB2 O43741 3/20 0.39
▸ PRKAG1 P54619 3/20 0.39
▸ PRKAA2 P54646 3/20 0.39
▸ PRKAA1 Q13131 3/20 0.39
▸ PRKAG3 Q9UGI9 3/20 0.39
▸ PRKAG2 Q9UGJ0 3/20 0.39
▸ PRKAB1 Q9Y478 3/20 0.39
▸ HAO2 Q9NYQ3 1/20 0.39
▸ PIM3 Q86V86 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10462527 0.86 CSNK2A1 (0.47) KDM4ECSNK2A1CSNK2A2CSNK2BHPGD
SCHEMBL29812480 0.83 KDM4E (0.51) KDM4ECSNK2A1CSNK2A2CSNK2BHPGD
SCHEMBL23148035 0.83 KDM4E (0.51) KDM4ECSNK2A1CSNK2A2CSNK2BHPGD
SCHEMBL1559220 0.82 CLEC4M (0.49) KDM4EALDH1A1
SCHEMBL23147026 0.81 KDM4E (0.46) KDM4ECSNK2A1CSNK2A2CSNK2BHPGD
SCHEMBL23147089 0.81 KDM4E (0.46) KDM4EHPGDHSD17B10DHODHALDH1A1
SCHEMBL1560707 0.76 PTGS2 (0.40) ALDH1A1
SCHEMBL19063709 0.74 BCL2L1 (0.44) KDM4EHPGDHSD17B10DHODHALDH1A1
SCHEMBL15486605 0.74 ELANE (0.42) NOTUM
SCHEMBL15485808 0.74 ALDH1A1 (0.51) KDM4EHPGDHSD17B10DHODHNOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12371428-B2 Pyridone compounds and methods of use EXELIXIS, INC. (US) 2025-07-29 — — US disclosed
US-20220315579-A1 PYRIDONE COMPOUNDS AND METHODS OF USE EXELIXIS, INC. 2022-10-06 — — US disclosed
EP-4034532-A1 PYRIDONE COMPOUNDS AND METHODS OF USE IN THE MODULATION OF A PROTEIN KINASE Exelixis, Inc. (US) 2022-08-03 — — EP disclosed
CN-114787144-A Pyridone compounds and methods for modulating protein kinases 埃克塞里艾克西斯公司 2022-07-22 — — CN disclosed
WO-2021062245-A1 PYRIDONE COMPOUNDS AND METHODS OF USE IN THE MODULATION OF A PROTEIN KINASE EXELIXIS, INC. (US) 2021-04-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12371428-B2 Pyridone compounds and methods of use PDXK, PLK2, MAP4K2 KDM4E 2816/4885CSNK2A1 302/4885CSNK2A2 327/4885
US-20220315579-A1 PYRIDONE COMPOUNDS AND METHODS OF USE PDXK, PLK2, MAP4K2 KDM4E 2816/4885CSNK2A1 302/4885CSNK2A2 327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback